Overview

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Status:
Completed

Trial end date:
2021-08-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie